Graybug Vision, Inc. files for IPO.

The IPO of Graybug Vision, Inc. will take place on September 24, 2020. It is a clinical-stage biopharmaceutical company specializing in the development of transformative medicines for the treatment of diseases of the retina and optic nerve. Retinal diseases such us wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy can lead to permanent loss of vision. For people with chronic retinal and optic nerve disorders the company develops medicines that make healthy vision more accessible.
 
The estimated valuation of the company after its IPO will be $289 million. SVB Leerink, Piper Sandler, Needham & Co. and Wedbush PacGrow are the IPO joint bookrunners.